AMD and PsiQuantum expanded their strategic partnership on November 12, 2026, to develop infrastructure for utility-scale, fault-tolerant quantum computers, with AMD planning an undisclosed equity investment in PsiQuantum. The companies will co-design computing infrastructure and applications combining quantum computing with high-performance computing and artificial intelligence. AMD will provide CPUs, GPUs, adaptive computing technology and software, while PsiQuantum will contribute its silicon photonics platform, which combines conventional chip technologies with optical networking. PsiQuantum’s drug-research technology is already running on AMD hardware and can produce more accurate results than existing methods, including initial breakthroughs in simulations of covalent inhibitors relevant to oncology drug discovery. The partnership comes amid growing investor interest in quantum computing for applications ranging from drug discovery to financial modeling and cryptography. It follows the Commerce Department’s planned $2 billion investment under the CHIPS Act, including a $100 million deal with PsiQuantum and minority equity stakes in nine quantum companies. The companies are also discussing a possible presence at Chicago’s Illinois Quantum and Microelectronics Park, but no location agreement has been finalized.